Biological properties of herpes simplex virus 2 replication-defective mutant strains in a murine nasal infection model

被引:40
作者
Jones, CA
Taylor, TJ
Knipe, DM
机构
[1] Harvard Univ, Childrens Hosp, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA
[2] Harvard Univ, Childrens Hosp, Sch Med, Div Infect Dis, Boston, MA 02115 USA
关键词
D O I
10.1006/viro.2000.0628
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We used a mouse nasal model of herpes simplex virus 2 (HSV-2) infection to examine the biological properties of HSV-2 wild-type (wt), TK-negative, and replication-defective strains in vivo. Nasal septa tissue is the major site of wt viral replication post intranasal (i.n.) inoculation. The HSV-2 strain 186 syn(+)-1 wt virus caused lethal encephalitis at doses of 10(4) PFU and above per nostril, and at lower doses no neurons in the trigeminal ganglia were positive for the latency-associated transcript, indicating a lack of latent infection. The 186 Delta Kpn TK-negative mutant virus replicated in nasal septa tissue but showed low-level replication in trigeminal ganglia at only one timepoint. In situ hybridization of trigeminal ganglia showed that the number of LAT-positive neurons was proportional to the inoculum dose from 10(3) to 10(6) PFU per nare. The replication-defective mutant virus 5B/acZ showed no replication in nasal septa tissue and no persistence of viral DNA at the inoculation site or the trigeminal ganglia. Nevertheless, inoculation of 5B/acZ or the double-mutant d/5-29 at distal sites reduced acute replication and latent infection of 186 Delta Kpn following intranasal challenge. This infection model provides a biological system to test the properties of HSV-2 strains and shows that replication-defective mutant strains do not persist at sites of inoculation or in sensory ganglia but can induce immune protection that reduces the latent viral load of a challenge virus. (C) 2000 Academic Press.
引用
收藏
页码:137 / 150
页数:14
相关论文
共 62 条
[1]   Suppression of Herpes simplex virus type 1 (HSV-1)-induced pneumonia in mice by inhibition of inducible nitric oxide synthase (iNOS, NOS2) [J].
Adler, H ;
Beland, JL ;
DelPan, NC ;
Kobzik, L ;
Brewer, JP ;
Martin, TR ;
Rimm, IJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (09) :1533-1540
[2]   NEUROPATHOLOGY OF HERPES-SIMPLEX VIRUS ENCEPHALITIS IN A RAT SEIZURE MODEL [J].
BEERS, DR ;
HENKEL, JS ;
SCHAEFER, DC ;
ROSE, JW ;
STROOP, WG .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1993, 52 (03) :241-252
[3]   EFFICACY OF RECOMBINANT GLYCOPROTEIN-D SUBUNIT VACCINES ON THE DEVELOPMENT OF PRIMARY, RECURRENT, AND LATENT GENITAL INFECTIONS WITH HERPES-SIMPLEX VIRUS TYPE-2 IN GUINEA-PIGS [J].
BERMAN, PW ;
VOGT, PE ;
GREGORY, T ;
LASKY, LA ;
KERN, ER .
JOURNAL OF INFECTIOUS DISEASES, 1988, 157 (05) :897-902
[4]   DNA immunization against experimental genital herpes simplex virus infection [J].
Bourne, N ;
Stanberry, LR ;
Bernstein, DI ;
Lew, D .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (04) :800-807
[5]   A Genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease [J].
Boursnell, MEG ;
Entwisle, C ;
Blakeley, D ;
Roberts, C ;
Duncan, IA ;
Chisholm, SE ;
Martin, GM ;
Jennings, R ;
Challanain, DN ;
Sobek, I ;
Inglis, SC ;
McLean, CS .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (01) :16-25
[6]   NEONATAL HERPES-SIMPLEX VIRUS-INFECTION - PATHOGENESIS AND TREATMENT IN THE GUINEA-PIG [J].
BRAVO, FJ ;
MYERS, MG ;
STANBERRY, LR .
JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (05) :947-955
[7]  
BURKE RL, 1991, VIROLOGY, V181, P793
[8]   HERPES-SIMPLEX VIRUS TYPE-2 ESTABLISHES LATENCY IN THE MOUSE FOOTPAD [J].
CLEMENTS, GB ;
SUBAKSHARPE, JH .
JOURNAL OF GENERAL VIROLOGY, 1988, 69 :375-383
[9]   GENITAL HERPES-SIMPLEX VIRUS-INFECTIONS - CLINICAL MANIFESTATIONS, COURSE, AND COMPLICATIONS [J].
COREY, L ;
ADAMS, HG ;
BROWN, ZA ;
HOLMES, KK .
ANNALS OF INTERNAL MEDICINE, 1983, 98 (06) :958-972
[10]   Genital herpes and public health - Addressing a global problem [J].
Corey, L ;
Handsfield, HH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (06) :791-794